Soluble Guanylate Cyclase Activators Tackling Drug Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological stimulation of soluble guanylate cyclase (sGC) for treating disorders associated with low cGMP levels, such as cardiovascular diseases, often leads to tolerance development and requires higher dosages due to reduced activity over time, and existing non-NO releasing sGC stimulators have weak effects on cGMP formation.
Innovation Solution
Development of specific compounds, represented by structural Formula I, which activate soluble guanylate cyclase, modulating cGMP production to treat and prevent diseases like hypertension, heart failure, and atherosclerosis, by increasing cGMP levels effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If organic nitrates are used to stimulate sGC, then sGC activation is achieved, but tolerance develops and activity reduces over time requiring higher dosages
Solution Approach 1:
The patent changes the chemical mechanism parameter from NO-releasing compounds to direct sGC binding compounds. This fundamental parameter change eliminates the tolerance development pathway while maintaining sGC activation, thereby resolving the contradiction between reliable activation and sustained treatment duration.
Solution Approach 2:
The patent introduces a new class of compounds that act as direct mediators between the drug molecule and sGC, bypassing the NO intermediate. This direct interaction mechanism prevents the adaptive responses that lead to tolerance, enabling consistent activation over extended treatment periods.
2Reliability
If conventional sGC stimulators are used, then some cGMP formation stimulation occurs, but the effect is weak and insufficient for therapeutic benefit
Solution Approach 1:
The patent optimizes multiple molecular parameters including the core heterocyclic structure, substituent positions, and electronic properties to maximize sGC binding affinity and activation potency. These parameter optimizations transform weak stimulators into potent therapeutic agents with sufficient cGMP formation stimulation.
Solution Approach 2:
The patent creates composite molecular structures combining specific heterocyclic cores with tailored substituent groups. This composite approach synergistically enhances both binding affinity and activation efficacy, achieving strong therapeutic effects that individual components cannot provide alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively activate sGC, leading to a strong increase in cGMP levels, providing therapeutic and prophylactic benefits for cardiovascular diseases without the drawbacks of tolerance development and dosage increase, offering a more potent treatment option.
Implementation Method 1
The binding of NO to the heme with formation of a penta-coordinate heme-nitrosyl complex is proposed as the mechanism of the activation by NO. The associated release of the histidine which is bound in the basal state to the iron converts the enzyme into the active conformation.
Data Source
AI summary
A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (" cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceuticall acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.